GXV 002
Alternative Names: GXV-002Latest Information Update: 10 Jan 2024
At a glance
- Originator Takeda
- Developer GEXVal
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pulmonary arterial hypertension
- Research Cardiomyopathies; Heart failure
Most Recent Events
- 10 Jan 2024 Early research in Heart failure in Japan (unspecified route) before January 2024 (GEXVal pipeline, January 2024)
- 09 Jan 2023 GEXVal plans to submit IND application for Pulmonary arterial hypertension (GEXVal pipeline, January 2023).
- 24 May 2022 GXV 002 is available for licensing as of 24 May 2022. https://gexval.com/en/vision-mission-and-strategy/